9 results about "Heterotopic ossification" patented technology

Systems for treating a targeted volume of muscle tissue to inhibit heterotopic ossification (HO) employ a delivery device including a reservoir containing a neuromuscular inhibitor and an injector assembly. The injector assembly can include an arrangement of needles and an injector operable to pass the neuromuscular inhibitor from the reservoir through the needles. The injector assembly can be configured to eject predetermined aliquots of a therapeutic dose of the neuromuscular inhibitor. The injector assembly can be shaped to compliment the targeted volume of muscle tissue within a larger volume of muscle tissue. The ejection of the predetermined aliquots can result in a therapeutic distribution of the therapeutic dose of the neuromuscular inhibitor within the targeted volume of muscle tissue that is sufficient to prevent formation of an HO lesion but insufficient to induce paralysis of the larger volume of muscle tissue.

The application discloses a multiple controlled-release drug-loaded coating modified anti-heterotopic ossification artificial temporomandibular joint prosthesis and a preparation method thereof, and comprises the following steps: surface treatment of a biomimetic artificial temporomandibular joint prosthesis; dopamine assisted co-deposition is adopted to sequentially form a DF-HA self-assembled nanosphere coating and a meloxicam liposome drug-loaded coating on the surface of the biomimetic artificial temporomandibular joint porous titanium prosthesis; and RGD is grafted on the surface of the meloxicam liposome drug-loaded coating by chemical natural deposition, and the anti-heterotopic ossification artificial temporomandibular joint prosthesis is obtained. The artificial temporomandibular joint prosthesis is modified by active drug-loaded meloxicam liposomes on one hand, and the artificial temporomandibular joint prosthesis is modified by RGD-DF-HA layered drug loading on the other hand, long-term slow release and programmed release of drugs are realized, anti-inflammatory effects are achieved, the purpose of treating and preventing heterotopic ossification after artificial joint replacement is achieved, long-term stability of artificial joint replacement is beneficial, early prevention, intervention, service life of the artificial joint prosthesis is improved, and the life quality of patients is improved.

The present disclosure provides methods of treating nongenetic heterotopic ossification and other MMP mediated conditions. Such methods are directed to inhibiting active MMP or inhibiting activation of MMP in therapeutic applications. Such methods include use of anti-MMP-9 antibodies directed to inhibiting MMP-9. These methods avoid the deleterious effects of treating nongenetic heterotopic ossification and other MMP mediated conditions with broad spectrum MMP inhibitors.

The application discloses a hydrogel spray for preventing traumatic ectopic ossification, a preparation method and a spraying device. The hydrogel spray comprises photocured hydrogel and nano drug-loaded complex loaded with curcumin, the nano drug-loaded complex is uniformly dispersed in the photocured hydrogel to form the hydrogel spray; the preparation method comprises the process of ultrasonic dispersion of the nano drug-loaded complex in the photocured hydrogel; and the spraying device comprises a spray container containing the hydrogel spray and a spraying head. The hydrogel spray has strong penetration capacity, is convenient to operate, does not cause stimulation to human gastrointestinal tract, and can be used for long-term prevention of traumatic ectopic ossification.

The present disclosure provides methods and compositions for treating non hereditary heterotopic ossification and genetic heterotopic ossification, such as fibrodysplasia ossificans progressive (FOP). Such methods are directed to MMP-9 inhibition in therapeutic applications.

This disclosure provides methods and compositions for treating non-hereditary heterotopic ossification and hereditary heterotopic ossification such as progressive ossifying fibrous dysplasia (FOP). These methods involve MMP-9 inhibition in therapeutic applications.

The invention discloses application of lycoris radiata exosomes in preparation of a medicine for treating ectopic ossification, and belongs to the technical field of biological medicine. According to the prepared dried lycoris radiata exosome La-dEXOs, osteoclast differentiation and osteoblast differentiation experiments and animal experiments prove that the prepared La-dEXOs can improve ectopic ossification of rats by promoting osteoclast differentiation and inhibiting osteoblast differentiation. Experimental results show that La-dEXOs has the potential to be developed into related medical products for preventing and treating ectopic ossification.

The application provides a kind of polypeptide and its application in bone defect repair, belong to polypeptide technical field.The application is based on the functional domain of TGF-beta 3 factor, designs 10 derived peptides, only selects one derived peptide with bone inductive property, the derived peptide is composed of 21 amino acid residues;The polypeptide can not only induce murine bone marrow mesenchymal stem cells to produce mineralization nodule in vitro, but also can induce new bone formation in rat skull extreme bone defect model (in vivo) and rat intramuscular (heterotopic ossification model), and the osteogenic induction efficiency is equivalent to BMP-2.Summing up, the polypeptide provided by the application has bone inductive property, and has great application prospect in bone defect repair.